Strike Bio

Strike Bio is a Dallas-based biotechnology company developing a novel class of RNA-based therapeutics designed to activate the innate immune system specifically within tumor cells. Founded on the research of Dr. Zhijian "James" Chen from UT Southwestern, the company utilizes its proprietary S.T.R.I.K.E. platform to deliver RNA molecules that trigger the STING (Stimulator of Interferon Genes) pathway. This approach aims to induce a potent, localized immune response against cancer while minimizing systemic toxicity. The company is currently in the pre-clinical stage, focusing on the development of treatments for various solid tumors. Strike Bio is backed by prominent venture capital firms including The Column Group.